Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
NYSE: NVO DEADLINE REMINDER: Berger Montague Reminds Nordisk A/S (NYSE: NVO) Investors of Important Class Action Lawsuit Deadline
11:36am, Thursday, 04'th Sep 2025
PHILADELPHIA , Sept. 4, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Novo Nordisk A/S.
Class Action Filed Against Novo Nordisk A/S (NVO) - September 30, 2025 Deadline to Join - Contact The Gross Law Firm
08:45am, Thursday, 04'th Sep 2025
NEW YORK , Sept. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28,
Global drugmakers rush to boost US presence as tariff threat looms
02:09pm, Wednesday, 03'rd Sep 2025
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Healthy Returns: Novo Nordisk's head of research and development previews the first-ever obesity pill
02:08pm, Wednesday, 03'rd Sep 2025
Novo Nordisk's Martin Holst Lange preveiwed the company's obesity pill, while OpenAI launches new initiative to speed up scientific discovery.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
12:21pm, Wednesday, 03'rd Sep 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
12:00pm, Wednesday, 03'rd Sep 2025
LOS ANGELES, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on b
NEW YORK , Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).
Should You Buy Novo Nordisk Stock Now or Wait?
09:00am, Wednesday, 03'rd Sep 2025
In this video, I will talk about the recent updates regarding Novo Nordisk (NVO -0.16%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Is Novo Nordisk Stock a Buy Now?
05:07am, Wednesday, 03'rd Sep 2025
Danish pharmaceutical giant Novo Nordisk (NVO -0.16%) recently turned a lot of heads with exciting news regarding Wegovy, its anti-obesity treatment.
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
03:07am, Wednesday, 03'rd Sep 2025
LOS ANGELES , Sept. 3, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo Nordisk" o
Investors who lost money on Novo Nordisk A/S (NVO) should contact Levi & Korsinsky about pending Class Action - NVO
03:51pm, Tuesday, 02'nd Sep 2025
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Tuesday, 02'nd Sep 2025
LOS ANGELES , Sept. 2, 2025 /PRNewswire/ -- The Law Offices of Frank R.
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such i
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
09:44am, Tuesday, 02'nd Sep 2025
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) investors o
